Abstract
Lung cancer kills approximately 1.3 million citizens in the world annually. The tyrosine kinase inhibitors (TKI) erlotinib and gefitinib are effective anti-tumor agents especially in lung cancer patients with epidermal growth factor receptor (EGFR) mutations. The goal is to increase the potency of TKI in lung cancer patients with wild type EGFR. G protein-coupled receptors (GPCR) transactivate the wild type EGFR in lung cancer cells. The GPCR can be activated by peptide agonists causing phosphatidylinositol turnover or stimulation of adenylylcyclase. Recently, nonpeptide antagonists were found to inhibit the EGFR transactivation caused by peptides. Nonpeptide antagonists for bombesin (BB), neurotensin (NTS) and cholecystokinin (CCK) inhibit lung cancer growth and increase the cytotoxicity of gefitinib. The results suggest that GPCR transactivation of the EGFR may play an important role in cancer cell proliferation.
Keywords: Epidermal growth factor receptor, G protein-coupled receptor, lung cancer, non-peptide receptor antagonists, peptide receptor agonists, transactivation of tyrosine kinase receptors.
Current Drug Targets
Title:EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer
Volume: 17 Issue: 5
Author(s): Terry W. Moody, Bernardo Nuche-Berenguer, Taichi Nakamura and Robert T. Jensen
Affiliation:
Keywords: Epidermal growth factor receptor, G protein-coupled receptor, lung cancer, non-peptide receptor antagonists, peptide receptor agonists, transactivation of tyrosine kinase receptors.
Abstract: Lung cancer kills approximately 1.3 million citizens in the world annually. The tyrosine kinase inhibitors (TKI) erlotinib and gefitinib are effective anti-tumor agents especially in lung cancer patients with epidermal growth factor receptor (EGFR) mutations. The goal is to increase the potency of TKI in lung cancer patients with wild type EGFR. G protein-coupled receptors (GPCR) transactivate the wild type EGFR in lung cancer cells. The GPCR can be activated by peptide agonists causing phosphatidylinositol turnover or stimulation of adenylylcyclase. Recently, nonpeptide antagonists were found to inhibit the EGFR transactivation caused by peptides. Nonpeptide antagonists for bombesin (BB), neurotensin (NTS) and cholecystokinin (CCK) inhibit lung cancer growth and increase the cytotoxicity of gefitinib. The results suggest that GPCR transactivation of the EGFR may play an important role in cancer cell proliferation.
Export Options
About this article
Cite this article as:
Moody W. Terry, Nuche-Berenguer Bernardo, Nakamura Taichi and Jensen T. Robert, EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer, Current Drug Targets 2016; 17 (5) . https://dx.doi.org/10.2174/1389450116666150107153609
DOI https://dx.doi.org/10.2174/1389450116666150107153609 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Omega-3 Polyunsaturated Fatty Acid Derived Lipid Mediators and their Application in Drug Discovery
Current Medicinal Chemistry Prevention of Non-communicable Diseases by Balanced Nutrition: Population- specific Effective Public Health Approaches in Developing Countries
Current Diabetes Reviews Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy Investigating the Molecular Basis of Drug Action and Response: Chemocentric Genomics and Proteomics
Current Drug Targets Involvement of Leukotriene Pathway in the Pathogenesis of Ischemia- Reperfusion Injury and Septic and Non-Septic Shock
Current Vascular Pharmacology Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?
Current Cancer Therapy Reviews Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling
Current Cancer Drug Targets Etoposide: Discovery and Medicinal Chemistry
Current Medicinal Chemistry Recent Advances in the Analyses of Carotenoids and Their Role in Human Health
Current Pharmaceutical Analysis Docetaxel-loaded Bovine Serum Albumin Nanoparticles Conjugated Docosahexaenoic Acid for Inhibiting Lung Cancer Metastasis to Bone
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present)
Recent Patents on Anti-Cancer Drug Discovery Oncolytic Virotherapy for Breast Cancer Treatment
Current Gene Therapy Micro-/Nano-Scale Biointerfaces, Mechanical Coupling and Cancer Therapy
Current Topics in Medicinal Chemistry Metabolomics-based Approach to Pharmacotherapy Personalization: Advantages and Limitations
Current Pharmacogenomics and Personalized Medicine Molecular Mechanisms of Liver Cancer
Anti-Cancer Agents in Medicinal Chemistry MicroRNA Regulation of TRAIL in Renal Carcinoma: Tiny Juggernauts at Work
Current Molecular Pharmacology The Link Between Conventional and Novel Anti-Cancer Therapeutics with Thrombotic Microangiopathy
Drug Metabolism Letters Structure-activity Relationship Studies of New Marine Anticancer Agents and their Synthetic Analogues
Current Medicinal Chemistry Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1
Current Cancer Therapy Reviews Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials